Podcasts about Cart

In this week's episode, Blood Associate editor Dr. Hervé Dombret interviews authors Drs. Sarah K. Tasian and David T. Teachey on their contributions to the How I Treat Series on acute lymphoblastic leukemia. Dr. Tasian's paper, “How I treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults” discusses the different classes of Ph-like ALL and reviews the recent trials investigating TKIs and immunotherapy specifically for this high-risk patient population. Dr. Teachey's paper, “How I treat ETP-ALL in children”, discusses the best current and emerging therapies that may be used in patients with ETP ALL, including nelarabine and other new agents, immunotherapy, and allogeneic HSCT.See the full How I Treat series in volume 145 issue 1 of Blood.

This month Alt.Latino's been looking at the music of Venezuela from a lot of different angles. For this episode, we've invited trumpet player and producer Ella Bric to be our guest DJ. She shared what she thinks are the most socially, culturally and politically impactful pieces of music to come out of Venezuela in the last half century.Ella Bric grew up in a migrant-rich town in Venezuela called San Antonio de los Altos, surrounded by a culturally-minded, socially conscious community. She's now based in New York, and in recent years has positioned herself as a prolific producer on the rise in the Latin music space. In 2018, she won a Latin Grammy for Producer of the Year, and she says her art comes from a curiosity about the state of the world and her desire to reflect that.(00:00) Introduction(01:46) La Vida Bohème, 'Hornos del Cal'(06:41) Betsayda Machado & Parranda el Clavo, 'Sentimiento'(11:35) María Rodríguez, 'Los Dos Titanes'(15:11) Ali Primera, 'Techos de Cartón'(19:52) Linda Briceño & Orlando Watson, 'Unfinished Song'(24:38) Desorden Público, 'Politicos Paraliticos'(27:36) Bucle Lunar, 'Subió El Maldito Dolar'This podcast episode was produced by Noah Caldwell. The executive producer of NPR Music is Suraya Mohamed.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

This month we've been looking at the music of Venezuela from a lot of different angles. For this episode, we've invited trumpet player and producer Ella Bric to be our guest DJ. She shared what she thinks are the most socially, culturally and politically impactful pieces of music to come out of Venezuela in the last half century.Ella Bric grew up in a migrant-rich town in Venezuela called San Antonio de los Altos, surrounded by a culturally-minded, socially conscious community. She's now based in New York, and in recent years has positioned herself as a prolific producer on the rise in the Latin music space. In 2018, she won a Latin Grammy for Producer of the Year, and she says her art comes from a curiosity about the state of the world and her desire to reflect that.(00:00) Introduction(01:46) La Vida Bohème, 'Hornos del Cal'(06:41) Betsayda Machado & Parranda el Clavo, 'Sentimiento'(11:35) María Rodríguez, 'Los Dos Titanes'(15:11) Ali Primera, 'Techos de Cartón'(19:52) Linda Briceño & Orlando Watson, 'Unfinished Song'(24:38) Desorden Público, 'Politicos Paraliticos'(27:36) Bucle Lunar, 'Subió El Maldito Dolar'This podcast episode was produced by Noah Caldwell. The executive producer of NPR Music is Suraya Mohamed.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.In this episode, Dr Matulonis sat down with guest Rebecca Porter, MD, PhD. Dr Porter is a physician at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School.Drs Matulonis and Porter discussed the evolving role of immunotherapy in gynecologic cancer management, focusing on recent clinical breakthroughs and future directions. They noted that although high-grade serous ovarian cancer has historically been refractory to immunotherapy, the phase 3 KEYNOTE-B96 trial (NCT05116189) demonstrated an efficacy benefit with the addition of pembrolizumab to weekly paclitaxel for patients with platinum-resistant disease. In particular, improvements in overall survival were noted in the PD-L1–positive patient population. Dr Porter attributed this success to the metronomic weekly dosing of paclitaxel, which may increase neoantigen levels and favorably alter the tumor microenvironment (TME).Moreover, the experts highlighted how immunotherapy has already become the standard of care for patients with mismatch repair–deficient advanced or recurrent endometrial cancer. However, they explained that for the mismatch repair–proficient population, this benefit is less clear and appears most significant in patients with measurable disease or specific molecular subtypes. They added that although circulating tumor DNA (ctDNA) assay results correlate with treatment outcomes, ctDNA is currently not an actionable biomarker for determining treatment duration or selection.Lastly, Drs Matulonis and Porter reported that the field of gynecologic oncology is shifting toward combination therapies and novel platforms beyond standard checkpoint inhibitors. Treatment advances include bispecific and trispecific antibodies that engage multiple cell types or signals; as well as adoptive cellular therapies, such as CAR T-cell and CAR natural killer–cell therapies. Ultimately, the experts concluded that the goal of managing challenging-to-treat diseases like ovarian cancer is to use combinatorial approaches—incorporating vaccines, anti-angiogenic therapies, and chemotherapy—to overcome the immunosuppressive nature of the TME.

This month, the gals invite Brandon Schexnayder from Southern Gothic on to chitchat about ghost gaslighting, sexy sheep, party raccoons, a porta-potty problem, and a brand-new fear for Amanda. Tune in for January's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.  

Dr. Marilia Bernardes, Infectious Diseases Faculty at the Morsani College of Medicine in Tampa, FL, presents an overview of the immune system. Dr. Bernardes skillfully breaks down the immune system into 4 distinct pillars and then its individual biological components. She presents the “who,” “what” and “why” for neutrophils, B-cells, and T cells and covers cellular and humoral immune deficits. She also covers newer immunotherapies such as BTK inhibitors, CAR-T and bispecifics, as well as biologics and other small molecules. Some rapid-fire cases are also presented to integrate the listener’s understanding of the material presented.

Send us a textAs we prepare for an incredible winter storm of historic measure, I have been to the store a few times to prep. Well, so has everyone else. It's been slammed, and yet people have been kind, sharing, and helpful as this little community has banded together to help each other endure a harsh weekend. Preparation is not panic, in fact it's expected by God with many things. But so also is sharing and generosity, it's why God gives us the things that he does in the first place. But we also must remember, no amount of preparation will sustain were it not also for the grace of God. We must give him glory and praise the one in whom we live and move and have our being. #SetYourMindAbovePodcast

Send us a textIn this special Flashcast episode of the WTR Small-Cap Spotlight podcast, Tim Gerdeman sits down with WTR Healthcare analyst Robert Sassoon to discuss his Initiation of Coverage Report on Anixa Biosciences. Their conversation explores Anixa's two clinical‑stage programs—one, an innovative CAR‑T cell therapy for terminal ovarian cancer patients, and the other, a breast cancer vaccine designed for both treatment and prevention. They review Phase 1 results, upcoming 2026 milestones, and how Anixa differentiates itself through both its scientific platforms and disciplined financial management.

Jorge Natan recebe Luiza Sá e Sergio Lobo para analisar vitória no clássico contra o Vasco, com a estreia do elenco profissional. Confira debate sobre as escolhas para os próximos jogos

Merci à Mathilde, Christophe, David et Sonia d'être venus raconter leur histoire sur Legend.David et Sonia ont 42 ans d'écart, Christophe et Mathilde 28. Pour Legend, ils ont accepté de raconter leur rencontre, leur quotidien, ainsi que les défis, les préjugés et les avantages de vivre avec une personne beaucoup plus jeune ou beaucoup plus âgée.Retrouvez toutes les informations concernant nos invités par ici ➡️Mathilde et ChristopheLeur compte Instagram ➡️ https://www.instagram.com/28ansdecart/Leur compte TikTok ➡️ http://tiktok.com/@28ansdecart David et Sonia Leur compte Instagram ➡️ https://www.instagram.com/unejeuneunvieux/Leur compte TikTok ➡️ https://www.tiktok.com/@unejeuneunvieux Pour prendre vos billets pour le LEGEND TOUR c'est par ici ➡️ https://www.legend-tour.fr/ Retrouvez la boutique LEGEND et nos offres pendant les soldes ➡️ https://shop.legend-group.fr/Retrouvez l'interview complète sur YouTube ➡️ https://youtu.be/oTAtRxuOm38 Pour toutes demandes de partenariats : legend@influxcrew.comRetrouvez-nous sur tous les réseaux LEGEND !Facebook : https://www.facebook.com/legendmediafr Instagram : https://www.instagram.com/legendmedia/ TikTok : https://www.tiktok.com/@legend Twitter : https://twitter.com/legendmediafr Snapchat : https://t.snapchat.com/CgEvsbWV Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Heavy leaves or fine dust—what's slowing you down? We break down the real-world tradeoffs between the most popular pool vacuum systems so you can match the right tool to every stop and cut your cleaning time without cutting corners. Drawing on years in the field, we compare Riptide and Hammerhead cart rigs, the updated Power Vac handheld, and the ultra-portable Bottom Feeder and Shrimp. We also spotlight the Vac Daddy's secret weapon for vacuum-to-waste jobs and explain how bag micron choices and cartridge filtration can completely change your results on dusty routes.We start with carts and cords, looking at why Riptide's intake shape delivers massive pull and how its rugged head and locking bags boost durability—while adding weight and tougher bag removal. Hammerhead counters with nimble balance and faster maneuvering thanks to its center wheel and lighter feel. From there, we explore battery options, cord lengths, and mounting solutions like T-bar receivers that let you carry multiple carts and gear without cramming the truck bed.Then we get practical about portables. Bottom Feeder and Shrimp turn speed into a strategy: flip the switch, drop in, and clean routine pools quickly with no cord management. With the cartridge filter assembly grabbing down to fine dirt, these compact tools can outperform expectations on dusty pools and tight decks. We compare micron ratings across bags, share the sweet spot that balances leaves and silt, and lay out when a cartridge wins over a small-micron bag. Finally, we carve out space for the Vac Daddy, which excels as a lightweight vacuum-to-waste solution that can replace bulkier portable filtration when you need to bypass the filter fast.• pros and cons of cart vacuums versus portable systems• riptide power and durability trade-offs• hammerhead balance and maneuverability• power vac handheld update and availability• bottom feeder and shrimp portability and runtime• cartridge assembly for fine dirt capture• bag micron choices and performance• vac daddy use case for vacuum-toSend us a textSupport the Pool Guy Podcast Show Sponsors! HASA https://bit.ly/HASAThe Bottom Feeder. Save $100 with Code: DVB100https://store.thebottomfeeder.com/Try Skimmer FREE for 30 days:https://getskimmer.com/poolguy Get UPA Liability Insurance $64 a month! https://forms.gle/F9YoTWNQ8WnvT4QBAPool Guy Coaching: https://bit.ly/40wFE6y

Jarrod had no idea this was coming.I pulled him into a lightning round: 13 foods that are in our grocery cart on repeat, power fueling our bodies, and consistently costing us less than what we used to spend eating the old way. Cruciferous vegetables that fight cancer. Beans that reverse other “chronic” disease. Berries that slow aging. The leafy greens that protects your heart. The list just keeps going!And the thing is, this isn't some expensive, boutique health food shopping. This is real life, six people in our household, buying in bulk, eating more than we ever did before, and being freed from the things that were REALLY costing us: missing all the opportunities we wanted to take in life but couldn't because we were stuck in all the exhausting health struggles.) You'll hear exactly what we buy, why we buy it, how we use it, and the strategic thinking behind building the grocery cart that fuels your ability to make kingdom impact instead of feeding future medical bills or “managing” a growing list of symptoms. There's no fluff or “theory” here, just the exact foods sitting in our kitchen right now that keep us showing up strong for what God called us to do.So if you're done with standing in the grocery store overwhelmed and not knowing what actually works, this episode hands you the blueprint. Thirteen foods, real results. Your body, your bank account, and the people needing what you can offer are about to have something amazing to celebrate!Time to fill your cart with abundant life!

Featuring perspectives from Dr Sagar Lonial and Dr María-Victoria Mateos, including the following topics:  Introduction (0:00) Best of ASH Multiple Myeloma (1:56) Case: A man in his late 50s with t(11;14) IgA kappa myeloma discovered during workup for new Stage IV kidney disease who has a chest wall plasmacytoma receives daratumumab with CyBorD and radiation therapy to the plasmacytoma with minimal response — Jeremy Lorber, MD (8:35) Antibody-Drug Conjugates and Other Emerging Novel Therapies for Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lonial (16:58) Case: A man in his mid 80s with severe obesity and coronary artery disease, chronic heart failure and sleep apnea receives belantamab mafodotin with low-dose pomalidomide for multiregimen-relapsed myeloma — Neil Morganstein, MD (27:57) Case: A man in his mid 60s with a history of stroke with aphasia receives teclistamab for multiregimen-relapsed MM after daratumumab, proteasome inhibitors, immunomodulatory drugs and selinexor — Justin Favaro, MD, PhD (34:42) Integrating Chimeric Antigen Receptor (CAR) T-Cell Therapy and Bispecific Antibodies into the Management of R/R MM — Dr Mateos (39:09) Case: A man in his early 70s with kappa light chain myeloma experiences complete response on cilta-cel CAR T-cell therapy with hypogammaglobulinemia requiring IVIG and develops melanoma of the abdominal wall — Bhavana (Tina) Bhatnagar, DO (52:07) Case: A man in his mid 50s with heavily relapsed MM who received multiple prior lines of therapy, including CAR T-cell therapy, receives talquetamab — Priya Rudolph, MD, PhD (55:44) CME information and select publications

We're barrel-blasting onto the main feed in 2026! Come for the expert analysis of Epic Universe's Donkey Kong coaster; stay for the discussion of which Kong characters are dating. The year may be new, but PTR is still up to its old tricks!"Chuck's Arcade" episode is up at: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon.com/PodcastTheRide⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠FOLLOW PODCAST: THE RIDE:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/PodcastTheRide⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/podcasttheride⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BUY PODCAST: THE RIDE MERCH:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.teepublic.com/stores/podcast-the-ride⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠PODCAST THE RIDE IS A FOREVER DOG PODCAST⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://foreverdogpodcasts.com/podcasts/podcast-the-ride⁠ See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Osteosarcoma Webinar Series: Joseph Skeate, PhD, an Assistant Professor at the University of Minnesota, discusses his OutSmarting Osteosarcoma funded work (Because of Annaleigh) on next generation dual-CAR gamma delta T cells for the treatment of pediatric osteosarcoma.In this presentation, Dr. Skeate will provide an overview of the next-generation genome engineering strategies deployed for this project and share updates on the development of a gamma-delta chimeric antigen receptor (CAR) T cell therapy for treating osteosarcoma. He will describe how the team is combining non-viral transposon insertion of a CAR transgene with targeted gene modification using an Adenine Base Editor to enhance T cell function in the presence of suppressive factors characteristic of osteosarcoma tumors.Dr Joseph Skeate is an Assistant Professor in the Division of Pediatric Hematology/Oncology at the University of Minnesota. He obtained his PhD in Medical Biology from the University of Southern California Keck School of Medicine. Following his doctoral work, he completed a postdoctoral fellowship at the University of Minnesota under the mentorship of Drs Branden Moriarity and Beau Webber. During this time, he developed a hyperactive transposon system and deployed novel genome engineering approaches using Cas9 systems, creating a powerful toolkit for rapid non-viral engineering and preclinical testing of primary human cells. Leveraging his background and expertise in immunology and genome engineering, his lab now focuses on developing next-generation cellular therapies for rare pediatric disease, including osteosarcoma.

We love to hear from our listeners. Send us a message.Welcome to episode 120 of Cell & Gene: The Podcast. Host Erin Harris is joined by Rachel Haurwitz, CEO of Caribou Biosciences, to discuss the company's progress in developing CRISPR-edited, off-the-shelf CAR-T therapies for hematologic malignancies. Their conversation centers on Vispacell, Caribou's allogeneic CD19 CAR-T for second-line large B-cell lymphoma. Haurwitz explains how Caribou has systematically optimized its allogeneic platform using clinical and translational data. They also cover pivotal Phase 3 trial planning, regulatory considerations, and what to expect next from Caribou's broader pipeline, including its BCMA-targeted program in multiple myeloma.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

In this week's episode, Blood Associate editor Dr. Thomas Ortel interviews authors Drs. Ware Branch and J.J. Strouse on their contributions to How I Treat hematologic complications in pregnancy. Dr. Branch's paper, “How I diagnose and treat antiphospholipid syndrome in pregnancy” discusses the evolving clinical and laboratory features of APS, and the treatment of cases meeting ACR/EULAR classification criteria. Dr. Strouse stresses the unique problems posed to both the mother and fetus during pregnancy in his paper "How I treat sickle cell disease in pregnancy”.See the full How I Treat series in volume 143 issue 9 of Blood journal. 

Oncologist George Georges, MD, moderates a discussion with Christine Hsieh, MD, rheumatologist, and Arjun Seth, MD, neurologist, on advancing care for inflammatory myopathies. The panel introduces the Northwestern Medicine Myositis Clinic, a one-stop model that simplifies diagnostics and connects patients to clinical trials. They review current treatment strategies — steroids, IVIg, steroid-sparing agents, rituximab, and JAK inhibitors — along with approaches for refractory disease. The panel also explores cellular therapies, including CAR-T cell trials.

If your body feels tense, wired, or constantly “on,” this episode is for you.An overactive nervous system doesn't mean something is wrong — it means your body has been under sustained stress without enough opportunities to fully downshift.In part one of this short Capacity Expansion series, I'm breaking down why your nervous system feels overactive and walking you through three science-backed tools you can use in real time to help your body shift out of fight-or-flight.In this episode, you'll learn:Why your nervous system reacts to modern stressors the same way it reacts to danger What's actually happening in your body when you feel anxious, overwhelmed, or on edge Three simple, effective ways to regulate your nervous system in the moment Why stillness and “just calming down” often don't work when you're activated How real-time regulation creates the foundation for lasting capacity expansionThis episode is about relief — learning how to come back into your body when your system is activated.In part 2, we'll talk about why tools don't always stick and what actually changes your baseline so you're not constantly regulating just to get through the day.Enrollment for Burnout Recovery Blueprint is open now, and we begin next week. Cart closes Friday, January 16 at midnight EST.

Ce mercredi 14 janvier, l'écart qui se creuse entre les revenus aux États-Unis et dans les pays de l'Union européenne, ainsi que la préférence européenne en matière de marchés publics, ont été abordés par Guillaume Dard, président de Montpensier Arbevel, Éric Heyer, directeur du Département analyse et prévision à l'OFCE, et André Loesekrug-Pietri, président de Joint European Disruptive Initiative (JEDI), dans l'émission Les Experts, présentée par Raphaël Legendre sur BFM Business. Retrouvez l'émission du lundi au vendredi et réécoutez la en podcast.

Wiggity, wiggity, wiggity, WAGS! Wild on 7th's most popular show of the season has arrived! The WAGS are BACK. For those of you that don't know what that means...it's W(ives) A(nd) G(irlfriend)s, and it almost always is a complete banger of a show. This week we welcome back Captain of the WAGs Danielle Spurgeon and a new face on the pod, Mama Moose aka Natascia Foligno. The ladies grace us with some amazing insight into their own and their husbands lives, and share some laughs with the guys. Carts and King jump around the league a bit to kick things off. They weigh in on Cart's youth hockey tourney madness, pond hockey with Anders Lee and the New York Islanders, Sergei Fedorov retirement ceremony, and more. Late in the show, we are joined by Stacey Nutini, founder of "Ladies of the NHL" Facebook groups who are doing amazing charity work, and just bringing ladies together under their shared love of NHL hockey teams around the league. It's a long one this week, but it's all amazing, so get after it, and drop a like or a comment on what you think.

Luccas Riedo é engenheiro civil e ex-CEO do G4 Educação. Após uma carreira executiva de sucesso, ele tomou uma decisão radical: vendeu tudo, saiu do mundo corporativo e alocou 100% do seu patrimônio em Bitcoin.Neste episódio, Luccas explica a lógica por trás dessa aposta "all-in". Ele detalha como o sistema financeiro atual opera como um mecanismo de confisco (via inflação e impostos), revela o risco real de bloqueios judiciais que o motivou a buscar soberania e discute a tese da "Greve dos Produtores" (inspirada em A Revolta de Atlas).Uma aula sobre economia, a história do dinheiro e como é possível viver de Bitcoin sem nunca precisar vendê-lo.Disponível no youtube:Link: https://youtu.be/J-kKBUHZgkYPatrocinador:Remessa Online - Envie e receba dinheiro do exterior com taxas mais baixas e sem burocracia.Link: ⁠https://www.remessaonline.com.br/?utm_medium=display&utm_source=Excepcionais&utm_campaign=RM_Podcast_Excepcionais_Awareness-202500:00:00 - Introdução: O sistema é baseado em confiança (e ela está acabando)00:02:25 - Por que alocar 100% do patrimônio em Bitcoin?00:03:30 - A história dos bancos e a fraude da reserva fracionária00:05:10 - 1971: O fim do padrão ouro e o início da impressão infinita00:08:19 - A inflação real é 17% (IPCA é uma mentira?)00:11:53 - A dívida impagável dos EUA e o roubo do futuro00:13:33 - A estratégia do governo para se perpetuar no poder00:18:17 - Bitcoin como "Opt-out": A saída do sistema00:20:14 - O risco de bloqueio judicial (Alexandre de Moraes e STF)00:22:45 - Escassez absoluta: Bitcoin vs Imóveis e Ouro00:28:06 - As 3 opções: Ignorar, Mudar o Sistema ou Se Proteger00:31:26 - Renda Fixa é Perda Fixa? (A conta real do prejuízo)00:34:17 - O segredo: Como viver de Bitcoin sem vender (Empréstimo Colateral)00:38:55 - A estratégia da MicroStrategy e empresas comprando Bitcoin00:44:18 - Como funciona a rede (Nodes) e por que não podem mudar as regras00:50:44 - Os riscos reais: Computação Quântica e Bugs00:55:07 - Custódia: Como guardar seu Bitcoin com segurança (Seed Phrase)01:08:28 - O Governo te rouba 3 vezes: Passado, Presente e Futuro01:09:48 - A Revolta de Atlas: O dilema de "entrar em greve" e parar de produzir01:15:02 - Vivendo na prática: Cartão de Crédito com Bitcoin01:21:28 - O ciclo do Bitcoiner: De Hater a Maximalista01:33:00 - A diferença brutal entre Bitcoin e "Cripto" (Ethereum, Solana)01:40:07 - Como começar a estudar (Dicas de livros e "100 horas")Siga o Luccas no Instagram:⁠https://www.instagram.com/luccasriedo/Nos Siga:Marcelo Toledo: ⁠https://www.instagram.com/marcelotoledoInstagram: ⁠https://www.instagram.com/excepcionaispodcastTikTok: ⁠https://www.tiktok.com/@excepcionaispodcast

In this Omni Talk Retail episode, Vipul Chawla, CEO of Singapore's FairPrice Group, reveals how their "Store of Tomorrow" has eliminated four critical friction points and delivered jaw-dropping results. From smart shopping trolleys that auto-generate your list to Vision AI that learns unusual patterns without programming, Vipul breaks down how omnichannel retail innovation drives an 70-80% increase in basket size and 82% self-checkout adoption. He shares insights on frictionless experiences, AI-powered store management tools, endless aisle integration, and why even senior customers are embracing these technologies. If you've ever wondered what purposeful retail innovation looks like at scale, this interview is for you!

durée : 00:03:16 - Le Fil éco - 22% d'écart salarial femmes-hommes, en France, en 2023. Comment expliquer une telle différence ? Discrimination, hiérarchie, qualification, temps partiel, choix sous contraints... Et si cette inégalité ne se jouait pas seulement sur la fiche de paie ? - réalisation : Cassandre Puel

Episode #364 - How Many Abandonment Emails Is Too Many? (Browse vs Cart vs Checkout) Every ecommerce founder I know has two fears that live side-by-side: "Don't annoy my audience"… and "Don't leave money on the table." Abandonment flows hit both fears at the exact same time.

Broadcast from KSQD, Santa Cruz on 1-01-2025: An emailer asks about omega-3 supplementation for memory at age 72. Dr. Dawn advises checking that fish oil capsules contain adequate DHA—at least 1,000 mg—since many omega-3 products have low DHA levels. She notes Medicare covers the same testing at standard labs as proprietary labs like OmegaQuant that charge patients directly. Beyond omega-3s, she emphasizes glucose control (hemoglobin A1c below 5.6) since the enzyme that breaks down insulin also clears beta-amyloid, and weight training to raise brain-derived neurotrophic factor (BDNF), which promotes new synapse formation essential for memory. Dr. Dawn reviews Popular Science's top 2025 health innovation: eye drops from Lens Therapeutics containing aceclidine that correct age-related farsightedness for 10 hours. The drops shrink the pupil to increase depth of field, improving near vision by three or more lines on eye charts within 30 minutes without affecting distance vision. Side effects include eye irritation, dimmed night vision, and headache. She describes Duke University's breakthrough allowing heart transplants from circulatory death donors using an on-table reanimation technique. This could expand the pediatric donor pool by 20%—critical since up to 20% of children die waiting for transplants. Dr. Dawn celebrates CAR-T immunotherapy for multiple myeloma, which saved her husband's life. Of 97 heavily pretreated patients, 38% achieved complete remission still present at five years, with over 50% total survival. The therapy removes T-cells, uses CRISPR to add receptors targeting cancer cell antigens, then reinfuses the modified cells. She highlights a UC Davis study showing remote blood pressure monitoring with home technology, education, and coaching dropped patients' average blood pressure from 150/80 to 125/74 in months—low-tech with high impact. Dr. Dawn explains the Nano Knife for prostate cancer, which uses localized electrical pulses delivered through thin wires to destroy tumors while sparing surrounding nerves. This minimally invasive approach could reduce erectile dysfunction and incontinence common with traditional surgery. She describes Gilead's Sunlenca, a twice-yearly injection for HIV prevention that's 99% effective. At $14,000 per injection in the US, proceeds help fund access in resource-limited countries where it can be distributed like a vaccination. Dr. Dawn discusses Journavx (suzetrigine), a new non-opioid pain medication working on sodium channels to block pain signals before reaching the brain. At $30 for 50 pills on GoodRx, it offers an alternative for surgical pain in patients with addiction history or genetic vulnerability to opioid dependence. She details the landmark case of Baby KJ, the first person to receive personalized CRISPR gene therapy. Born with a CPS1 enzyme deficiency causing toxic ammonia buildup, KJ was too small for liver transplant. Scientists identified his specific mutation and used CRISPR base editing delivered via lipid nanoparticles to correct a single DNA letter—changing an A to G—in his liver cells which restored enough function to be discharged home. Dr. Dawn reports surprising findings that COVID mRNA vaccines amplify cancer immunotherapy. Lung cancer patients who received COVID vaccination within 100 days of checkpoint inhibitor treatment had 56% three-year survival versus 31% for unvaccinated patients. The mechanism is unknown but may involve mRNA generally alerting the immune system. She revisits research showing Zostavax shingles vaccination reduced dementia risk by 20% over seven years. A natural experiment in Wales—where an age cutoff created comparable vaccinated and unvaccinated groups—provided strong evidence that preventing herpes zoster inflammation protects brain health. Dr. Dawn concludes with Huntington's disease breakthrough: microRNA therapy delivered by virus directly into the brain slowed disease progression by 75% over three years. The microRNA binds to Huntington protein mRNA, preventing ribosome translation and toxic protein production. Some patients returned to work; others expected to need wheelchairs are still walking.

REDIFF - Lola se sent mise à l'écart et en manque de chaleur dans sa relation avec son plus jeune fils, récemment marié. Elle éprouve des difficultés à s'adapter à la nouvelle dynamique familiale, notamment en raison de différences sociales et culturelles avec la belle-famille. Elle cherche à comprendre comment maintenir une relation chaleureuse avec son fils tout en gérant ses propres sentiments de solitude et d'insécurité. Chaque soir, en direct, Caroline Dublanche accueille les auditeurs pour 2h30 d'échanges et de confidences. Pour participer, contactez l'émission au 09 69 39 10 11 (prix d'un appel local) ou sur parlonsnous@rtl.fr.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

This week's episode accompanies the Review Series on Marginal Zone Lymphoma published in this week's issue of Blood. Associate editor, Dr. Philippe Armand interviews authors Dr. Juan Pablo Alderuccio and Dr. Ariela Noy on their contribution to this review series titled "The treatment of marginal zone lymphoma". The article is crucial in highlighting the clinically and biologically heterogenous nature of MZL diseases, and how current treatment options and available research do not allow for comprehensive MZL specific therapies. Drs. Alderuccio and Noy share their insights on specific avenues for the expansion of the MZL care landscape. Find the full review series in volume 147 issue 2 of Blood journal.

​ This week we discuss stem cells.  Having great therapeutic and biotechnological potential, stem cells are extending the frontier in medicine. Not only replace dysfunctional or damaged cells, the so-called regenerative medicine, stem cells may also offer us new perspectives regarding the nature of aging and cancer. This review will cover some basics of stem cells, their current development, and possible applications in medicine. Meanwhile, important remaining challenges of stem cell research are discussed as well. ​Stem cells are unique, unspecialized cells that can divide to create more stem cells (self-renewal) and can transform (differentiate) into various specialized cells, acting as the body's repair system to generate new cells for growth, repair, and maintenance, with different types existing in embryos (pluripotent) and adults (multipotent) and being studied for treating diseases like paralysis, diabetes, and heart disease.   Types of Stem Cells Embryonic Stem Cells: Pluripotent (can become almost any cell type) and come from early embryos.  Adult Stem Cells (Tissue-Specific): Multipotent (limited to certain cell types within their tissue) and found in adult organs like bone marrow, skin, and the brain.  Induced Pluripotent Stem Cells (iPSCs): Adult cells reprogrammed in the lab to act like embryonic stem cells, offering a path to personalized medicine.  ​Sources of Stem Cells Embryos (for research), Umbilical cord blood, Bone marrow, Other adult tissues (like fat or skin). ​Medical Significance (Stem Cell Therapy) Regenerative Medicine: Uses stem cells to repair or replace damaged tissues and organs.  Treatments: Already used to treat blood cancers (like leukemia) through bone marrow transplants.  Research Focus: Investigated for treating conditions such as spinal cord injuries, Parkinson's, Alzheimer's, heart disease, and diabetes.  ​There is some stem cell controversy, primarily centering on the ethics of using human embryos, particularly embryonic stem cells, which hold vast potential for medicine but require destroying the embryo, raising moral debates about the embryo's status as human life, with opponents seeing it as the destruction of life and proponents viewing it as a moral imperative to cure disease, though adult stem cell research and induced pluripotent stem cells (iPSCs) offer less controversial avenues.  We don't discuss this aspect of the therapeutic use but if you are interested you can find out more with a simple internet search. ​Stem cell therapy in the US is not banned but restricted. Only FDA-approved products (such as cord blood transplants and CAR-T cell therapies for blood conditions) are fully legal. Other uses are allowed only in limited cases under the 361 HCT/P pathway.

Dr. Lisa Hicks and Dr. Joseph Mikhael discuss the updated guideline from ASCO and Ontario Health (Cancer Care Ontario) on the treatment of multiple myeloma. They cover recommendations for therapeutic options across smoldering multiple myeloma, transplant eligible multiple myeloma, transplant ineligible multiple myeloma, and relapsed or refractory multiple myeloma. They highlight the importance of shared decision making and patient-centric care. They comment on the explosion of new treatment options in this space and the impetus for this guideline becoming a living guideline, which will be updated on an ongoing, regular basis. Read the full guideline, "Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline" at www.asco.org/hematologic-malignancies-guidelines. TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/hematologic-malignancies-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02587   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Lisa Hicks from St. Michael's Hospital and University of Toronto, and Dr. Joseph Mikhael from the Translational Genomics Research Institute, an affiliate of City of Hope Cancer Center, co-chairs on "Treatment of Multiple Myeloma: American Society of Clinical Oncology-Ontario Health (Cancer Care Ontario) Living Guideline." Thank you for being here today, Dr. Hicks and Dr. Mikhael. Dr. Lisa Hicks: Thanks so much. Dr. Joseph Mikhael: It is a pleasure to be with you, Brittany. Thank you. Brittany Harvey: Before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Hicks and Dr. Mikhael who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into what we are here today to talk about, Dr. Mikhael, I would like to start by recognizing that this guideline updates the 2019 ASCO-CCO Guideline on the Treatment of Multiple Myeloma. So what prompted this update and what is the scope of this updated guideline? Dr. Joseph Mikhael: It is amazing when we think back in myeloma years, 2019 actually seems a very, very long time ago because really so much has changed in myeloma over these last six to seven years. Indeed, there have been over 150 randomized controlled trials that we didn't have at the prior guideline that we reviewed for this. Myeloma is a disease that has really changed so dramatically over these last several years. Multiple new agents have been introduced. We now have CAR-T cell therapy, bispecific antibodies, and multiple other agents that were not available at the time. Furthermore, with this growing complexity, it is becoming more important than ever to be able to provide practical advice and guidelines to the oncology community. For most oncologists, they have less than 5% of their time dedicated to multiple myeloma. It is important to bring a clarity to them that allows them to care for their patients. And the scope of these guidelines, furthermore, really cover the whole spectrum of myeloma. They go further than our prior guideline where now we have included smoldering multiple myeloma along with frontline therapy and relapsed multiple myeloma. So, we have really tried to provide the full spectrum to our colleagues in oncology to ensure that they have the tools they need to provide the best care possible for their patients. Dr. Lisa Hicks: That is a really terrific summary. And maybe one thing I will just add is it is really unique to have this much literature. I can't think of another guideline that I have ever been involved with that has seen a field move so quickly and develop so many advancements in a period of just over four or five years. Brittany Harvey: Certainly, there is a large volume of evidence that you all had to review for this guideline update. I think to your point probably one of the greater volumes of literature for a guideline update that you both mentioned. Based on that, I would like to review the key recommendations that are updated in this guideline. So Dr. Hicks, that new patient population that Dr. Mikhael mentioned earlier, what are the key recommendations for patients with smoldering multiple myeloma? Dr. Lisa Hicks: So this is the first time that an ASCO guideline is addressing this branch of multiple myeloma care. It is an area where I think some guidance is needed, and smoldering myeloma is not an active cancer. And so one thing that I really want to highlight is that the panel felt very strongly that to recommend any therapy in this space we needed a higher level of evidentiary certainty, of evidentiary confidence, to make recommendations for active therapy. The panel really made two very important recommendations. First of all, the panel did not recommend treatment for low or intermediate risk smoldering myeloma. That is important. And then the area where I think for the first time we have recommended consideration of treatment is patients with high risk smoldering myeloma. And for patients with high risk smoldering myeloma, the panel recommended that it was appropriate to consider either treatment with daratumumab or careful observation. Dr. Joseph Mikhael: And I think that move forward as you have mentioned, Dr. Hicks, is particularly important because it is an area to some degree still of equipoise and many trials are going on in the area. But we do now have a strong phase III trial that supports the use of daratumumab monotherapy for three years when compared to close observation. But of course, that is not for everyone. And one of the key themes of all of our recommendations are going to be now that more and more choices are available, that we have discussions with our patients to ensure that we match the right treatment with the preference of the patient. And I think that is particularly important here in smoldering myeloma. Dr. Lisa Hicks: Multiple myeloma care and the multiple myeloma evidence is really so nuanced, and one of the nuances that readers will appreciate if they read the guideline is that how smoldering myeloma is risk stratified has been different across different trials. And that really adds to the complexity of this recommendation and is one of the reasons that the panel felt that it was appropriate to recommend either observation or treatment. Brittany Harvey: It is great to have these new recommendations for this unique patient population. And as you both mentioned, that individualized patient care is really important across this entire guideline. So then following those recommendations, Dr. Mikhael, what is recommended for initial therapy, autologous stem cell transplantation, post transplant therapy, and measurement of response for patients with transplant eligible multiple myeloma? Dr. Joseph Mikhael: Well, that is an area that has really considerably also grown since the last guideline. Obviously one would have to consult the guidelines to get every last detail, but in essence, we want to assess whether or not patients are transplant eligible or ineligible. And that assessment is not based on age or renal function alone, but indeed on a careful assessment of that patient. When that assessment is made and deemed that a patient is transplant eligible, our recommendation is that a patient typically would receive a quadruplet. That is to say, a monoclonal antibody directed against CD38, a proteasome inhibitor, an immunomodulatory drug, and dexamethasone to be given for approximately four to six cycles followed by the stem cell transplant, followed by potentially another two cycles of consolidation, and then maintenance therapy. A couple of important caveats. One, we do have two different CD38 antibodies that can be used, either daratumumab or isatuximab. Although typically bortezomib is the preferred proteasome inhibitor, consideration can be given to carfilzomib by virtue of the potential toxicity from bortezomib. And then lastly in the maintenance setting, we are typically recommending at least lenalidomide alone, but consideration can be given to dual maintenance therapy as the data is emerging to either add to that daratumumab or carfilzomib. All the while using the IMWG criteria for response. The goal of course is to achieve the deepest response possible and to maintain that response until such time as patients would relapse. Finally, the length of maintenance therapy continues to be an area of equipoise and study in multiple myeloma. And so at minimum, patients would receive two to three years of maintenance therapy, and based on risk status and depth of response it can be considered that patients would potentially come off maintenance therapy, of course always with the caveat that toxicity would influence length of therapy as well. Brittany Harvey: Yes, as you mentioned, evaluating which patients are eligible is extremely important for considering what is recommended in the guideline for both transplant eligible and transplant ineligible patients. So then Dr. Hicks, following those recommendations for transplant eligible multiple myeloma, what are the recommended treatments, goals of therapy, and measurement of response for patients with transplant ineligible multiple myeloma? Dr. Lisa Hicks: You know, I really can't emphasize enough how important an individualized patient assessment is. When we are thinking about the range of patients that are included in this category of transplant ineligible patients, it is a huge range. You may have fairly fit patients in their late 70s all the way to patients in their 90s. And we really want to see that treatments are tailored both to the fitness of the patient, their individual circumstances, and their preferences. And it is a wonderful thing to have lots of options for patients in this circumstance. What the guidelines have recommended for most patients who are transplant ineligible but fit enough for a stronger therapy is quadruplet therapy. So actually therapy that is very similar to what is being recommended in the transplant eligible population but for a longer period of time. And then for those patients who for whatever reason, be it their fitness or their preference, are not appropriate for that quadruplet therapy, the recommendation is for triplet therapy with a combination of lenalidomide, bortezomib, dexamethasone, or very often, more often in most cases, an antibody based approach with an anti-CD38 plus lenalidomide plus dexamethasone. Dr. Joseph Mikhael: The only thing I would add to that, I think we have to also, as we do mention in our recommendations, be particularly cautious with the dosing of these medications. Because even though we think of them as a single agent or a particular class, there can be quite a variation within the dosing regimen that can affect a patient's side effects and their quality of life. And so being very careful with dose modifications, and particularly in the transplant ineligible patient, is an important part of the recommendation as well. Dr. Lisa Hicks: Yeah, this is a podcast so no one can see me nodding vigorously that dose modification is so important particularly with those older and frailer patients, and with particular attention to trying to reduce dexamethasone doses and favoring weekly administration of bortezomib when that drug is used. Brittany Harvey: Absolutely. Considering the risks and benefits and patient preferences is really key to selecting therapy for these patients. So then Dr. Mikhael, for the final overarching patient population addressed in this guideline, for patients with relapsed or refractory multiple myeloma, what treatment options are recommended? Dr. Joseph Mikhael: This of course is, if you will, the biggest part of the guideline because there has been so much done in the relapse setting. And I think we start the guideline by saying a decision has to be made as to when to institute therapy. That there may be some patients with slow biochemical relapse that may be monitored for a period of time. But when the decision is made to initiate treatment, instead of a simple algorithm, the guideline emphasizes the fact that there are multiple choices that can be given to a patient that are going to match what comorbidities the patient has, what they have been treated with before, and of course what their preferences are. I think we highlight two particular areas. That now that CAR-T cell therapy is available as early as first relapse, it should be a consideration by virtue of the fact that it has resulted in such deep and durable responses. But that triplets should also be considered in that earlier relapse setting because we do have multiple classes of agents that can be used. We know that in later relapse options exist including bispecific antibodies for which we have four different choices. And that in general, patients will ultimately receive either a triplet or CAR-T cell therapy in earlier relapse, but there are some patients who may be eligible only for a doublet by virtue of their comorbidities and of their prior therapies. Lastly, it really does emphasize the point as we have mentioned a few times in this podcast, and I am so glad it keeps coming up, is that as I often say we don't treat myeloma, we treat people. And engaging the patient in that conversation to ensure that the right treatment gets matched to the right patients is particularly important because with all the new classes that we have with antibody drug conjugates, with XPO1 inhibitors, the traditional three classes of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, along with as we have already mentioned CAR-T and bispecific antibodies, it really is an incredible laundry list of choice. And making that choice specific to the patient becomes absolutely critical. I should also lastly note that there are patients who may defer their initial transplant. There may be patients who may be eligible for a second transplant. So autologous stem cell transplant, although primarily used in the frontline setting, may still be a consideration for a smaller subset of patients in the relapse setting. Dr. Lisa Hicks: I think maybe one thing that I would add is an overarching principle which is actually similar to a principle in the first guideline, and that is that in the relapsed or refractory setting, there are many different treatment options. And in fact, the number of treatment options feels like it is evolving every day. But an overarching principle for clinicians to consider is to try and choose combinations of drugs that the patient has either not been exposed to in the past or certainly that they are not refractory to. We really want to be pulling new options out of the toolbox as much as we can. Dr. Joseph Mikhael: Very often we do see where someone may be on a triplet and they are progressing on it and someone just changes out one drug. We have suggested not to take that approach but to take the approach of completely introducing a new therapy when someone is progressing on their current therapy. I think that point is particularly important and the consensus panel was very clear. Brittany Harvey: Understood. That is very helpful when thinking about what options to offer to patients in the relapsed and refractory setting. And as you mentioned earlier, the figures in this guideline provide an outline of options and then the tables really go into some of the details and outcomes of the trials, and those are very helpful for clinicians to refer to. So then Dr. Hicks, we have talked a little bit about some of the nuances of the guideline, but what should clinicians know as they implement these new and updated recommendations? Dr. Lisa Hicks: I think they should feel comfortable that these are trustworthy guidelines. So these are evidence-based guidelines that have been rigorously developed after a very thorough evidence review and put together by a panel of experts who were extremely thoughtful in their review of the evidence. And so all of this contributes to the trustworthiness of the guidance. And then I would also encourage people to take a deep look at the guidelines because of the importance of nuance that is addressed in them, and then to also explore some of the tools that ASCO is developing that helps with implementation including the flow charts that are contained within the guidelines and some additional tools that are available online. Brittany Harvey: Absolutely. The tools and resources for this guideline are available online with the publication and we will provide links to that in the show notes of the episode. So then following that, Dr. Mikhael, how does this guideline update affect patients with multiple myeloma? Dr. Joseph Mikhael: As we sort of intimated earlier, I like to say I don't treat myeloma, I treat people. I think we should always be patient-centric and patient-focused. And I think in the discussion we always were. We always wanted to ensure that multiple factors go into a decision-making process. We are not just looking at the biology of the disease, we are looking at patient factors. Those patient factors include their frailty as we commented in a frailty assessment, their preferences, their comorbidities. And I think, in a day where we have so many choices, we emphasize in the guideline the importance of that conversation with the patient. That, if you will, shared decision-making model where options are laid out and based on the patient factors and the treatment factors they can then be meshed together in the best way so that patients can make the right choice. And of course in conjunction with the guidelines, we have patient friendly summaries of them. And we involved, of course, patients in the development of these guidelines. And I think that is one of the greatest strengths of the ASCO guidelines is that there is a patient with us at the table who is giving their perspective on the guideline as we go forward. So I am very thankful that we have created a product that is, if you will, not only for the providers, the practitioners that are prescribing these agents and that are directly giving the care, but indeed for the very patients who of course have the most at stake here. Dr. Lisa Hicks: Yeah Joe, I am so glad you called out the participation of patient partners in the guideline. It is such an important part and they were really- the patient partner was such an important part of this panel in helping us understand the patient perspective as we developed this guidance. Brittany Harvey: Definitely. It is a hugely important role for the panel and for all of the panel including the patient partners and the experts in the disease to review the evidence and come up with comprehensive recommendations. And yes, as you mentioned, the individualized treatment and the shared decision-making is really paramount to this guideline. Finally, Dr. Hicks, you alluded to earlier the vast number of treatment options that is really exploding in multiple myeloma. And so this guideline is becoming a living guideline continuously updated by ASCO. So what are the outstanding questions regarding this topic and what evidence is the panel looking forward to for future updates? Dr. Lisa Hicks: I am really excited about this. This is one of the first guidelines that will be a living guideline for ASCO and it is such a good fit. You have heard Joe and I say a few times how quickly this field is moving, how complex the field is. I think everyone on the panel knew that no matter how quickly we did it and how deeply we reviewed the evidence, it was inevitable that more evidence would be generated as we were putting out the guideline. In a field like that, it is really important that we find a way to provide evidence-based guidelines quickly to the community. You know, waiting another five years, letting another 150 trials accrue before we do another guideline is not what the community needs. And so ASCO has really risen to this challenge and is committed to living guidelines. And so a living guideline is a guideline that commits to reviewing the evolving evidence on an ongoing basis, watching for practice changing trials, and having a standing panel that will review evidence and update recommendations on a regularly scheduled basis. So that is what a living guideline is, and that is what this guideline is becoming. That is just the first thing in terms of what a living guideline is. And then what are we watching? Well, honestly what aren't we watching? There is so much happening in multiple myeloma. We knew as we put the guideline out that there were trials in process, some trials that had been released at conferences but not yet published. We will be waiting for those and if they are practice changing they will be addressed in upcoming updates. There is new evidence just recently presented around combined anti-CD38 and bispecific antibodies. I don't know yet whether that will be addressed but I wouldn't be surprised if it was. There are so many things coming down the pipeline and it is just wonderful that there is going to be a way to try and address them in a robust fashion. Dr. Joseph Mikhael: Yeah I agree with you, Lisa. I can't think of another disease that would be more relevant for a living guideline. I mean we had difficulty because new data kept coming in as we were making recommendations. And so at some point we had to draw a line and say this is where we will stop and produce this guideline and have it ongoing. And I really look forward to seeing the updates because we know as you mentioned that there are so many things that are on the verge of approval and on the verge of changing the way we manage this terrible disease. And before I close, I would love to remind all of our listeners that as we commented from the start, patient engagement is critical at ASCO and in our guidelines process. Unfortunately we lost a very dear patient during the guidelines process, and that is Jack Aiello. Jack Aiello had been a patient and a patient advocate for many, many years in the myeloma community. And indeed we have actually dedicated these guidelines to his honor. And so I thought it would be valuable for us to mention that today. And we miss you Jack, but we are very grateful that we have been able to dedicate this excellent body of work to your memory. Brittany Harvey: Absolutely. This guideline and your dedication to him is an honor to his memory and we really recognize him in thinking about this guideline. We will look forward to those future trial results that you mentioned, Dr. Hicks, to update this guideline and continue to provide options for patients with multiple myeloma and improve upon those options and shared decision-making with patients. So I want to thank you both for all of your work to develop this guideline and for your time today, Dr. Hicks and Dr. Mikhael. Dr. Lisa Hicks: You are so welcome. Thanks for featuring this guideline. Dr. Joseph Mikhael: Thank you so much, Brittany. It has been a privilege. Brittany Harvey: Finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/hematologic-malignancies-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines App, which is available in the  Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Aurora returns from a dinner party with a new, dubious alliance with Draken. Frustrated, she attempts to seek council with the mysterious woman who calls herself her "friend" and discovers something about herself and her deepest desire. As Aurora contemplates her growing thirst for power, the lines between friend and foe blur even further, and the seeds of doubt and ambition begin to take root in her mind.A Tale of Remembrance serves as an integral mini-series within the Sword Art Online: AOD campaign, unveiling the enigmatic backstory of a pivotal character. It stands as a compelling prelude to the events of season 4.Contact Us:Email: info@missingrollplayerfound.comFollow Us:Website: https://missingrollplayerfound.com/Linktree: https://linktr.ee/rollfoundSupport Us: Please consider contributing to the production of the podcast.Patreon: https://patreon.com/missingrollplayerfoundDice Envy (affiliate): https://diceenvy.com/?rfsn=2188188.53cb38Battlebards (affiliate): https://battlebards.com/#/register/mrpfpodMusic Attribution: (To be updated)Dark Fantasy Studio (A Band in the Inn, Dark Echoes)Link: http://darkfantasystudio.com/Kevin Macleod (The Dread)Link: https://incompetech.com/Michael Ghelfi (Burning Fields with Distant Screams)Link: https://www.youtube.com/user/MichaelGhelfiMonument Studios (Anticipation Ambience, Astral Observatory, Horseback, Horse & Cart, Countryside, Evening in the City, Friendly Woodwinds, Quiet Tavern, Raided Village, Vigor)Link: https://www.monumentstudios.net/Music D20 (Helgisidur Just Percussion)Other Music and Sounds by Syrinscape Link: https://syrinscape.com/?att_missing_roll_player_found Because Epic Games Need Epic Sounds Support this podcast at — https://redcircle.com/missing-roll-player-found2852/donations

 Join hosts Raj, Ashwin, and Eddie in this episode of Blood Cancer Talks as they welcome Dr. Luciano Costa, the first author of the NEJM manuscript on the MajesTEC-3 RCT, which was presented at ASH 2025. This episode dives deep into the trial's topline findings, capturing the nuances of the patient population, efficacy and safety data, and the future implications for treatment. The episode also examines the comparative efficacy of bispecific T-cell engagers versus CAR-T therapies, along with spirited discussion on the potential for fixed-duration treatment in myeloma care. Episode Highlights Main Topics Covered MajesTEC-3 Trial: Teclistamab-Daratumumab vs. Standard of Care Trial design and patient populationPrimary endpoint: Progression-free survival (PFS)MRD negativity rates and depth of responseOverall survival and safety profileClinical implications for treatment selectionTreatment Selection in Early Relapse Comparing MajesTEC-3 and CARTITUDE-4 patient populationsFramework for choosing between bispecific antibodies vs. CAR T-cell therapyManaging anti-CD38 exposed patientsLink to the NEJM paper: https://www.nejm.org/doi/abs/10.1056/NEJMoa2514663  

Équipe suspendue, encadrement démis et mise à l'écart de Pierre-Emerick Aubameyang et Bruno Ecuele Manga : l'élimination au premier tour de la Coupe d'Afrique des Nations passe mal au Gabon, où le ministre des Sports a annoncé des sanctions. Face à la Côte d'Ivoire, la sélection gabonaise s'est inclinée (3-2) mercredi, pour la troisième fois en trois matches. Aubameyang se défend dans un tweet : "Je pense que les problèmes de l'équipe sont bien plus profonds que la petite personne que je suis".

In this week's episode we've pulled a vault recording from 2025! Blood editor Dr. Laurie Sehn interviews authors Drs. David-Alexandre Trégouët and Johannes Schetelig on their research published in volume 146 issue 19 of Blood journal. Dr. Trégouët's study conducted a genome-wide association study supplemented by transcriptome and Mendelian randomization analyses to identify 28 loci and proteins associated with VTE recurrence risk. This work provides genomic evidence that inherited variants contribute to the risk of VTE recurrence, raising the possibility of a more personalized approach to the prevention of recurrent VTE. The study conducted by Dr. Schetelig and colleagues report the results of a long term trial on patients with poor-response AML, comparing outcomes between patients who received salvage chemotherapy versus immediate transplantation. With no difference in survival rates at 5 years, outcomes seem to be determined mainly by genetic risk factors, age, and comorbidities, therefore challenging the routine use of intensive remission induction before allogeneic transplant in patients with an available donor and underscore the need for novel therapeutic strategies for poor-risk AML.Featured Articles:Molecular Determinants of Thrombosis Recurrence Risk Across Venous Thromboembolism Subtypes Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial 

REDIFF - Lola se sent mise à l'écart et en manque de chaleur dans sa relation avec son plus jeune fils, récemment marié. Elle éprouve des difficultés à s'adapter à la nouvelle dynamique familiale, notamment en raison de différences sociales et culturelles avec la belle-famille. Elle cherche à comprendre comment maintenir une relation chaleureuse avec son fils tout en gérant ses propres sentiments de solitude et d'insécurité.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Week 17 brought Evan another fresh batch of season-ending injuries and Frank the division title! The boys recap an embarrassing Saturday performance in Lambeau by the beleaguered Packers that handed the Bears the NFC North crown before their epic showdown in the Bay on SNF. Plus, a look forward at potential playoff scenarios for both teams and a not-so-civil discussion on the future of Matt LaFleur.

Breakthrough science has never been stronger — yet patients still miss life-saving therapies.Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery.The problem isn't discovery. It's how science, capital, and systems are aligned — or not.Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem.As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge scientific depth with incentives, execution, and real-world delivery. Capital follows speed and scale — not intention — and healthcare systems built decades ago are failing to keep up.In this episode, Alasdair Milton, Principal at KPMG, explains where innovation actually breaks — and what must change for cures to reach patients at scale. From diagnostics and data silos to capital allocation and prevention models, this conversation reframes the next decade of precision medicine.

What if the knowledge we depend on today... disappeared tomorrow? Have you ever wondered how much of humanity's greatest achievements have already been lost to time?Do you suspect that ancient civilizations knew things we are only now beginning to rediscover?Do you worry that our own digital civilization might be far more fragile than we think?If so... keep reading.For thousands of years, human knowledge has risen, vanished, and—sometimes—been found again.From medical breakthroughs in ancient Egypt to astonishing feats of engineering by cultures we barely remember, history shows a repeating pattern: discovery, prosperity... and catastrophic loss.Now, with our reliance on digital systems and complex global networks, we may be closer than ever to our own "forgotten age."https://jrbialik.com/Drawing on over 40 years of professional experience in engineering, technology, and history—including work with the U.S. Air Force, the Department of Homeland Security, and contributions to critical technology programs—Jack R. Bialik takes you on a journey across centuries of lost civilizations, vanishing wisdom, and the fragile threads holding our modern knowledge together.Here's a glimpse of what you'll discover inside Lost in Time: How cataract surgery was successfully performed in 2400 BC Egypt—and why we nearly lost that knowledge forever.The shocking truth about technologies invented thousands of years earlier than historians once believed.Forgotten disaster events that erased entire libraries of human understanding in a single day.The hidden risks of a fully digital society—and what history teaches us about protecting what matters.Lessons from the past that can guide business leaders, educators, and decision-makers today.How to recognize the warning signs of a coming knowledge collapse....and much more.You might think a book like this requires deep academic expertise to follow—it doesn't. Bialik's clear, compelling style makes these stories accessible for curious readers, history lovers, business travelers, and lifelong learners alike.If you're ready to explore the mysteries of humanity's greatest achievements—and learn how we can prevent them from disappearing again—scroll up and click "Add to Cart" now!Jack R. Bialik's 40-year career spans from Electrical Engineering and Project Management to biblical studies, with notable contributions to organizations like the U.S. Air Force and the Department of Homeland Security. His industry-impacting paper, presented at the Motorola System Symposium 2000, stands out among his many achievements. His unique expertise led him to be invited to be a reviewer for the White House's Broadband Technology Opportunities Program, marking another career highlight. Today, as the Chief Technology Officer of a niche Crypto-Mining company, he continues influencing the technology landscape. However, Jack's interests extend beyond his profession, with a certificate from the Awakening School of Theology and his interest in ancient history. His commitment to societal welfare is seen through his involvement with at-risk teens and clean water initiatives in Haiti. Jack is a consummate professional and committed humanitarian, exemplifying the power of lifelong learning and altruism.Become a supporter of this podcast: https://www.spreaker.com/podcast/earth-ancients--2790919/support.

Send us a textWe weren't planning on dropping another episode before the new year, but when the timing feels right, you listen.This is a special holiday re-share of my conversation with Vanessa Torres from Freedom a la Cart, an organization doing some of the most important, powerful work in our community.In this episode, Vanessa shares her personal story of surviving human trafficking and what real healing actually looks like when someone is met with safety, employment, community, and time. We talk about trauma bonds, recovery, motherhood, and the long road back to trust. Both in others and in yourself. It's honest, heavy at times, and deeply human.We're bringing this conversation back right now because Freedom a la Cart, like many nonprofits, was recently denied grant funding they were counting on. In response, their team launched an end-of-year giving campaign to help bridge the gap and continue supporting survivors during a season when the need is especially real.If this episode moves you, you'll find a link to their Freedom Matters campaign below. Whether you give, share, or simply listen with intention. Every bit of support matters.✨ Learn more or support their campaign here: https://freedomalacart.org/freedom-matters/Thank you for being here and for being part of a community that shows up when it counts.

This Editor's Special Episode of The HemOnc Pulse features Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discussing treatment strategies for relapsed/refractory multiple myeloma and where selinexor-based regimens fit in today's evolving landscape. Drawing from real-world cases, Dr. Richardson explores care for patients before CAR T, after CAR T relapse, and in between—highlighting how selinexor can be used flexibly across multiple lines, including as a bridge to future immunotherapies. The conversation emphasizes individualized, dynamic treatment planning to balance disease control, tolerability, and long-term goals in an increasingly complex era of myeloma care.

La tertulia semanal en la que repasamos las últimas noticias de la actualidad científica. En el episodio de hoy: Cara A: -Obituario: James Watson (10:00) -Regeneración de cartílago (48:50) Este episodio continúa en la Cara B. Contertulios: Luisa Achaerandio, Francis Villatoro, Borja Tosar, Héctor Socas. Imagen de portada realizada con Midjourney. Todos los comentarios vertidos durante la tertulia representan únicamente la opinión de quien los hace... y a veces ni eso

La tertulia semanal en la que repasamos las últimas noticias de la actualidad científica. En el episodio de hoy: Cara B: -Regeneración de cartílago (00:00) -Origen policlonal del cáncer colorrectal (27:40) -Batman en el metro (52:00) -SETI@HOME. Datos y resultados (1:22:30) Este episodio es continuación de la Cara A. Contertulios: Luisa Achaerandio, Francis Villatoro, Borja Tosar, Héctor Socas. Imagen de portada realizada con Midjourney. Todos los comentarios vertidos durante la tertulia representan únicamente la opinión de quien los hace... y a veces ni eso

In this week's episode, Blood editor Dr. James Griffin interviews authors Drs. Vincent Muczynski and Mark Geyer on their latest research published in Blood. Dr. Muczynski's research asks if there could there be a better gene than the factor VIII (FVIII) gene to transfer for curative treatment of hemophilia A? Dr. Geyer then explores CAR T cells armed with interleukin-18 (IL-18) secretion that target CD371, a transmembrane glycoprotein with high expression on AML and leukemia-initiating cells. Both studies explore finding novel targets for these powerful treatment modalities. Featured Articles:Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibodyCD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia

You know what's right. But what do you do when every gatekeeper says no? In this episode, Drew Ann Long, inventor of Caroline's Cart, shares the story of refusing to let a necessary idea die. Her vision was simple—and radical: a shopping cart that makes the retail experience accessible for people with disabilities and mobility challenges. The industry pushed back. Manufacturers said no. Retailers avoided the conversation. Funding didn't show up. So she invested personally and kept advocating for a need others wouldn't acknowledge, and stayed the course anyway. Despite the special needs community being the world's largest minority group, products designed for their needs are lacking. This creates a barrier to access not only for them but for their families and caregivers. By introducing more inclusive products like Caroline's Cart, the world was opened for those with mobility challenges, autism and dementia. Success means believing in your cause and taking risks to make it happen no mater what. When the establishment tells you no, cultivate support in the community you want to serve. Innovation happens when you focus on the solution not the problem. Contact Drew Ann: https://www.drewannspeaks.com/ Donate to Caroline's Cause scholarship fund: https://www.carolinescause.com/carolines-cause/

Send us a textTheOncoPT Podcast officially turned SEVEN, y'all! And a beautiful part of being around this long means that it's time for some knowledge updates:Bone Marrow Transplant (BMT) and CAR T-cell therapy are evolving fast—are you keeping up? In this episode of TheOncoPT Podcast, Dr. Adam Matichak returns to share the latest updates on these groundbreaking treatments and what they mean for your OncoPT practice.You'll learn how CAR T-cell therapy is expanding, why mobility strategies matter more than ever, and how to use vital signs to guide your treatment decisions. Plus, we'll explore how you can advocate for rehab's role in oncology, prepare patients for complex treatments like BMT and CAR T, and find the resources you need to stay ahead in this rapidly changing field.Whether you're new to cancer rehab or a seasoned pro, this conversation will give you practical tools to treat your patients undergoing BMT and/or CAR T-cell therapy. Listen now!Follow TheOncoPT on Instagram.Follow TheOncoPT on LinkedIn.

Après les foies gras, les chapons, le Champagne et les vins mousseux, on termine le repas de Noël avec un focus sur la bûche, le dessert emblématique, de plus en plus dans sa version glacée. Côté prix, c'est le grand écart : de 3 euros à 20 euros... Ecoutez Olivier Dauvers : les secrets de la conso du 23 décembre 2025.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

When a once-reliable podcast promo email suddenly tanks to 15% opens, you either keep pretending it's fine or you blow it up and rebuild it from scratch. You'll hear Jay Schwedelson and Amy Porterfield get honest about what changed in her newsletter, why “being more you” is now a real growth strategy, and how to experiment without freaking out when people unsubscribe.ㅤSubscribe to Amy Porterfield's newsletter, listen to The Amy Porterfield Show, and follow her on Instagram.ㅤBest Moments:(03:45) When 15% open rates forced a total newsletter reset.(05:03) Why letting your real personality show matters even more in the AI era.(07:06) Turning “YOUR cringe” feedback into a subject line that popped open rates.(08:06) The email metrics she still watches, and why beating your own baseline is the point.(13:10) Cart-close urgency is shifting, so she frontloads webinars in the first 48 hours.(17:12) The custom AI tool move that makes “just use ChatGPT” the wrong answer.ㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/

This month, the multitalented Tawny Platis joins the gals to tell stories of abstract art, an immersive job interview, Kim Crawford's betrayal, flying cornucopias, Mama Mia showdowns, a haunted footprint, and a woman who did not marry her brother. Tune in for December's episode of Gossip at the Corpse Cart! For more info on Tawny's many talents, go to https://tawnyvoice.com/ For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.  

Aaron & Tom review the state of the holiday retail climate, the history of America's vapor economics, the CNN x Kalshi collab, and financing Air Jordans at 22% interest. Subscribe to our patreon today: https://www.patreon.com/trillbillyworkersparty

This month, the gals bless us with their long-time bestie, the famous Blortney! Topics include guinea pig parties, overturned monkeys, a poopy pants puzzle, and eyebrow innovation. Don't be a stinker and a meanie, tune in for November's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.